BR0201004A - Compostos de triazina úteis como inibidores de sorbitol desidrogenase - Google Patents

Compostos de triazina úteis como inibidores de sorbitol desidrogenase

Info

Publication number
BR0201004A
BR0201004A BR0201004-6A BR0201004A BR0201004A BR 0201004 A BR0201004 A BR 0201004A BR 0201004 A BR0201004 A BR 0201004A BR 0201004 A BR0201004 A BR 0201004A
Authority
BR
Brazil
Prior art keywords
diabetic
inhibitor
compounds
sorbitol dehydrogenase
relates
Prior art date
Application number
BR0201004-6A
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0201004A publication Critical patent/BR0201004A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS DE TRIAZINA úTEIS COMO INIBIDORES DE SORBITOL DESIDROGENASE". Esta invenção refere-se a compostos inibidores de sorbitol desidrogenase com a fórmula I em que R^ 1^, R^ 2^ e R^ 3^ são tal como se define na memória descritiva. Esta invenção também refere-se a composições farmacêuticas contendo estes compostos, que inibem a sorbitol desidrogenase e a métodos de tratar ou de impedir complicações diabéticas, em especial a neuropatia diabética, a retinopatia diabética, a nefropatia diabética, a microangiopatia diabética, a macroangiopatia diabética, a cardiomiopatia diabética, e as úlceras nos pés, pela administração de tais compostos a um mamífero que sofra de diabetes e que esteja portanto em risco de vir a sofrer dessas complicações. Esta invenção também refere-se a composições farmacêuticas que incluam uma combinação de um composto com a fórmula I da invenção presente com um segundo agente farmacêutico, incluindo um inibidor de aldose reductase, um inibidor de permuta iónica de sódio hidrogênio (NHE-1), um inibidor de glicogêneo fosforilase (GPI), um inibidor seletivo de reabsorção de serotonina, um inibidor de 3-hidróxi-3-metilglutarilcoenzima A reductase, um inibidor do enzima de conversão de angiotensina, um agente anti-diabético de tiazolidinadiona, um antagonista de receptor de angiotensina II, um agonista de ácido <sym>-aminobutírico (GABA), um antagonista de fosfodiesterase de tipo 5, um agonista da adenosina, e um inibidor de CETP, e a métodos de utilizar estas composições de combinação.
BR0201004-6A 2001-03-30 2002-03-28 Compostos de triazina úteis como inibidores de sorbitol desidrogenase BR0201004A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28005001P 2001-03-30 2001-03-30

Publications (1)

Publication Number Publication Date
BR0201004A true BR0201004A (pt) 2003-01-07

Family

ID=23071429

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0201004-6A BR0201004A (pt) 2001-03-30 2002-03-28 Compostos de triazina úteis como inibidores de sorbitol desidrogenase

Country Status (6)

Country Link
US (1) US6894047B2 (pt)
EP (1) EP1247809A3 (pt)
JP (1) JP2002326987A (pt)
BR (1) BR0201004A (pt)
CA (1) CA2379791A1 (pt)
MX (1) MXPA02003323A (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0934061T6 (en) 1996-07-24 2015-01-26 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
JP2007534624A (ja) * 2003-07-16 2007-11-29 ニューロジェン・コーポレーション ビアリールピペラジニル−ピリジン類縁体
EP1670446A2 (en) * 2003-09-26 2006-06-21 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
WO2005037284A1 (en) * 2003-10-15 2005-04-28 Pfizer Products Inc. Sorbitol dehydrogenase inhibitor and hypertensive agent combinations
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
MY145822A (en) * 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
WO2008072850A1 (en) * 2006-12-11 2008-06-19 Amorepacific Corporation Triazine derivatives having inhibitory activity against acetyl-coa carboxylase
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
FR2948027A1 (fr) 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
US11083720B2 (en) 2017-03-17 2021-08-10 Regents Of The University Of Colorado, A Body Corporate Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670551B2 (de) * 1965-10-30 1973-01-25 Salze trisubstituierter s-triazine
DE178901C (pt) * 1968-02-08
DE3905364A1 (de) * 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
DE4025387A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als reagenzien
CA2145640C (en) * 1992-09-28 2001-01-30 Banavara L. Mylari Substituted pyrimidines for control of diabetic complications
AP2005003199A0 (en) * 1999-04-01 2005-03-31 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
EP1041068B1 (en) * 1999-04-01 2004-04-14 Pfizer Products Inc. Compounds for treating and preventing diabetic complications
AU3977001A (en) * 2000-02-15 2001-08-27 Sugen Inc Pyrrole substituted 2-indolinone protein kinase inhibitors

Also Published As

Publication number Publication date
EP1247809A2 (en) 2002-10-09
JP2002326987A (ja) 2002-11-15
US20030004166A1 (en) 2003-01-02
CA2379791A1 (en) 2002-09-30
MXPA02003323A (es) 2002-11-05
EP1247809A3 (en) 2003-12-17
US6894047B2 (en) 2005-05-17

Similar Documents

Publication Publication Date Title
EA200300673A1 (ru) Пиридазиноновые ингибиторы альдозоредуктазы
BR0201004A (pt) Compostos de triazina úteis como inibidores de sorbitol desidrogenase
BR9913433A (pt) Sistema desinfetante estabilizado composto de duas partes e composições e métodos a ele relacionado
PE20040374A1 (es) DERIVADOS DE ACIL-4-CARBOXIFENILUREA COMO INHIBIDORES DE LA GLUCOGENO FOSFORILASA a
HUP0402403A2 (hu) Cukorbetegség-ellenes hatású dipeptilpeptidáz IV (DP-IV) inhibitorok ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BR0009433A (pt) Inibidores de sorbitol desidrogenase
BRPI0509625A (pt) aglutinante hidráulico
NO20073024L (no) Kinaseinhibitorer
NO20072286L (no) Hemming av HCV NS3-NS4A-protease
Borowski et al. Characterization of imidazo [4, 5-d] pyridazine nucleosides as modulators of unwinding reaction mediated by West Nile virus nucleoside triphosphatase/helicase: evidence for activity on the level of substrate and/or enzyme
HUP0201314A2 (hu) Aril-szubsztituált pirazolok, imidazolok, oxazolok, tiazolok és pirrolok, valamint ezek alkalmazása és az ezeket tartalmazó gyógyászati készítmények
BR9912073A (pt) Composições farmacêuticas que compreendem 2-quinolonas
MA29746B1 (fr) Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l&#39;hepatite c
BR0000666A (pt) Aminas impedidas por grupos n-alcóxi, substituìdas por hidróxi
MA30602B1 (fr) Modulateurs du metabolisme, et traitement de troubles au moyen de ces modulateurs
BRPI0711121A2 (pt) derivados de benzonitrila substituìdos por glucopiranosila, composições farmacêuticas que contêm tais compostos, seu uso e processo para a sua fabricação
MA31763B1 (fr) Inhibiteurs de kinase de type polo
PE20100267A1 (es) Procedimiento para la preparacion de compuestos de aminocrotonilo
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
UY30387A1 (es) Nuevos compuestos
BR0308146A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BRPI0911035A2 (pt) ativadores de pirrolidinona glicoquinase
MA29926B1 (fr) Derives de pyrazine
RS50759B (sr) Formulacije gela 4-hidroksi-tomoksifena
BRPI0518706A2 (pt) composiÇÕes para tingimento de cabelos com alto teor de carbonato e/ou oxidante

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1980 DE 16/12/2008.